Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

EQUITY - Disclosure of changes in issued and outstanding share capital (Details)

v3.22.2.2
EQUITY - Disclosure of changes in issued and outstanding share capital (Details)
6 Months Ended
Jun. 30, 2022
shares
Disclosure of classes of share capital [line items]  
Common Shares issued in settlement of purchase consideration of a business combination 1,260,063 [1]
Beginning Balance 68,217,894
Common Shares issued as a result of options exercises 217,368
Ending Balance 69,695,325
Pharm Yarok  
Disclosure of classes of share capital [line items]  
Common Shares issued in settlement of purchase consideration of a business combination 523,700 [1]
Vironna  
Disclosure of classes of share capital [line items]  
Common Shares issued in settlement of purchase consideration of a business combination 485,362 [1]
Oranim  
Disclosure of classes of share capital [line items]  
Common Shares issued in settlement of purchase consideration of a business combination 251,001 [1]
[1] Pharm Yarok - 523,700, Vironna - 485,362, Oranim - 251,001